AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Highlights:
Frontier IP Group PLC celebrates a grant awarded to portfolio company The Vaccine Group (TVG) for developing cattle vaccines.
The £400,000 grant from Innovate UK, in collaboration with the Animal and Plant Health Agency, will support the use of TVG's innovative herpesvirus-based antigen delivery platform.
TVG previously received £1 million from Defra to create vaccine candidates for Streptococcus suis in pigs, indicating strong validation for its technology.
Frontier IP Group PLC (LSE:FIPP) has announced a significant development regarding its portfolio company, The Vaccine Group (TVG), which has secured a grant exceeding £400,000 from Innovate UK. This funding, awarded in collaboration with the Animal and Plant Health Agency, will facilitate the advancement of vaccines for cattle, leveraging TVG's novel herpesvirus-based antigen delivery platform.
Neil Crabb, chief executive of Frontier IP, expressed enthusiasm about the grant, noting its importance in validating TVG’s technology and enhancing its collaboration with esteemed organizations in the field. He emphasized that the number of awards and partnerships reflects the strength of TVG’s innovative approach to vaccine development.
The latest grant will focus on addressing critical health issues in cattle, specifically targeting bovine respiratory syncytial virus, a leading cause of illness among young calves in the UK, as well as the globally spreading lumpy skin disease. This initiative underscores the company’s commitment to improving animal health and welfare through innovative solutions.
TVG has also recently been awarded £1 million from Defra to develop vaccine candidates for Streptococcus suis, a significant health concern for pigs, in partnership with Plymouth and Cambridge universities. These accomplishments illustrate TVG’s ongoing efforts to advance its research and development capabilities within the agricultural and veterinary sectors.
Frontier IP holds a 17% stake in The Vaccine Group, further demonstrating its dedication to supporting the growth of innovative companies in its portfolio. Crabb remarked on the exciting potential of TVG, highlighting the company's focus on delivering transformative solutions in vaccine technology.
With these recent developments, Frontier IP Group continues to reinforce its position as a key player in fostering advancements in healthcare and agricultural innovation, paving the way for improved disease management in livestock.
